You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 8,036,835


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,036,835
Title:Probe design methods and microarrays for comparative genomic hybridization and location analysis
Abstract: Methods and systems for identifying and selecting nucleic acid probes for detecting a target with a nucleic acid probe array or comparative genome hybridization microarray, comprising selecting a plurality of potential target sequences, generating a plurality of candidate probes from the target sequences, filtering the plurality of candidate probes by analyzing candidate probes for selected probe properties in silico. Microarrays comprising probes selected by the methods of the invention are particularly useful for comparative genome hybridization and location analysis.
Inventor(s): Sampas; Nicholas M. (San Francisco, CA), Curry; Bo (Redwood City, CA), Tsang; Peter (San Francisco, CA), Lipson; Doron (Tel-Aviv, IL), Yakhini; Zohar H. (Ramat Hasharon, IL)
Assignee: Agilent Technologies, Inc. (Santa Clara, CA)
Application Number:12/797,521
Patent Claims:1. A computer-implemented method for generating a set of probe nucleic acid sequences, the method comprising: (a) sorting a plurality of candidate probe nucleic acid sequences, for a genomic region of interest, from smallest genomic distance to largest genomic distance between neighboring candidate probe nucleic acid sequences to produce a sorted plurality of candidate probe nucleic acid sequences; (b) evaluating a probe parameter for a neighboring pair of candidate probe nucleic acid sequences from said sorted plurality to identify a first member of said neighboring pair with a more desirable probe parameter than a second pair member of said neighboring pair; (c) removing said second pair member from said plurality; (d) reiterating said sorting, evaluating and removing steps at least once to generate a set of probe nucleic acid sequences; and (e) outputting said set of probe nucleic acid sequences wherein said method is performed by a computer that is programmed to perform said method.

2. The method according to claim 1, wherein said neighboring pair evaluated in step (b) is a pair that is closest to each other in terms of genomic distance in said sorted plurality.

3. The method according to claim 2, wherein said probe parameter is an in silico probe parameter.

4. The method of claim 3, wherein said in silico probe parameter is selected from a group consisting of duplex melting temperature, hairpin stability, GC content, probe is within an exon, probe is within a gene, probe is within an intron, probe is within a intergenic region, and homology score.

5. The method according to claim 1, comprising synthesizing at least one probe nucleic acid having a sequence of a member probe nucleic acid sequence of said set of probe nucleic acid sequences.

6. The method according to claim 5, wherein said method further comprises assaying said probe nucleic acid in a hybridization assay.

7. The method according to claim 1, comprising generating a nucleic acid array comprising at least one probe nucleic acid having a sequence of a member probe nucleic acid sequence of said set of probe nucleic acid sequences.

8. The method according to claim 7, wherein said method further comprises contacting said nucleic acid array with a genomic sample.

9. The method according to claim 4, wherein said evaluating comprises evaluating duplex melting temperature and wherein said first member has a lower duplex melting temperature than said second pair member.

10. The method according to claim 4, wherein said evaluating comprises evaluating homology score and wherein said first member has a higher homology score than said second pair member.

11. The method according to claim 1, wherein said plurality of candidate probe nucleic acid sequences are generated by: (i) selecting target sequences from said genomic region of interest; (ii) repeat-masking said target sequences to form non-repeat masked regions; (iii) tiling sequences across said non-repeat masked regions to generate said candidate nucleic acid sequences; and (iv) screening said candidate probes nucleic acid sequences according to at least one in silico parameter.

12. The method according to claim 11, comprising identifying restriction enzyme sites in the genomic region of interest, and selecting target sequences that exclude said restriction enzyme sites.

13. A non-transitory computer readable medium comprising instructions for performing the following method: (a) sorting a plurality of candidate probe nucleic acid sequences, for a genomic region of interest, from smallest genomic distance to largest genomic distance between neighboring candidate probe nucleic acid sequences to produce a sorted plurality of candidate probe nucleic acid sequences; (b) evaluating a probe parameter for a neighboring pair of candidate probe nucleic acid sequences from said sorted plurality to identify a first member of said neighboring pair with a more desirable probe parameter than a second pair member of said neighboring pair; (c) removing said second pair member from said plurality; (d) reiterating said sorting, evaluating and removing steps at least once to generate a set of probe nucleic acid sequences; and (e) outputting said set of probe nucleic acid sequences.

14. The non-transitory computer readable medium of claim 13, wherein said neighboring pair evaluated in step (b) is a pair that is closest to each other in terms of genomic distance in said sorted plurality.

15. The non-transitory computer readable medium of claim 14, wherein said probe parameter is an in silico probe parameter.

16. The non-transitory computer readable medium of claim 15, wherein said in silico probe parameter is selected from a group consisting of duplex melting temperature, hairpin stability, GC content, probe is within an exon, probe is within a gene, probe is within an intron, probe is within a intergenic region, and homology score.

17. The non-transitory computer readable medium of claim 16, wherein said evaluating comprises evaluating duplex melting temperature and wherein said first member has a lower duplex melting temperature than said second pair member.

18. The non-transitory computer readable medium of claim 16, wherein said evaluating comprises evaluating homology score and wherein said first member has a higher homology score than said second pair member.

19. The non-transitory computer readable medium of claim 13, where said plurality of candidate probe nucleic acid sequences are generated by: (i) selecting target sequences from said genomic region of interest; (ii) repeat-masking said target sequences to form non-repeat masked regions; (iii) tiling sequences across said non-repeat masked regions to generate said candidate nucleic acid sequences; and (iv) screening said candidate probes nucleic acid sequences according to at least one in silico parameter.

20. The non-transitory computer readable medium of claim 19, wherein said method comprises identifying restriction enzyme sites in the genomic region of interest, and selecting target sequences that exclude said restriction enzyme sites.

Details for Patent 8,036,835

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.